The Interferons plus Other Modalities of Cancer Therapy

  • John Wagstaff
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The year 1990 marked the tenth anniversary of the introduction of the recombinant alpha-interferons (IFN-alpha) into clinical trial. Although not fulfilling the expectations of the media that they would be the panacea for cancer, they have become an essential adjunct to the management of a number of human malignancies. The current thrust of clinical development of the IFNs is moving away from single agent usage and towards combined modality programmes incorporating other cytokines, monoclonal antibodies and chemotherapeutic agents. Single agent maintenance therapy with interferon, once a low volume disease state has been achieved by other treatments, is another approach which is proving to be of some value. The aim of this chapter is, therefore, to discuss the available data relating to the use of the IFNs in combination with these other treatment modalities.


Renal Cell Carcinoma Antitumour Effect Recombinant Interferon Advanced Colorectal Carcinoma Body Hyperthermia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Balkwill FR: Interferons. In: Cytokines in Cancer Therapy. Oxford University Press, Oxford 1989 pp 8Google Scholar
  2. 2.
    Balkwill FR: Interferons. Lancet 1989 (i):1060–1063CrossRefGoogle Scholar
  3. 3.
    Yoneda K, Yamamoto T, Osaki T: Influence of interferon on adriamycin uptake of cultured tumour cells. Int J Cancer 1989 (44):483–488PubMedCrossRefGoogle Scholar
  4. 4.
    Sarosy GA et al: Phase I study of α-2-interferon plus doxorubicin in patients with solid tumors. Cancer Res 1986 (46):5368–5371PubMedGoogle Scholar
  5. 5.
    Creagan ET et al: Phase I study of recombinant leukocyte A interferon (IFN-α2A, Roferon A) with doxorubicin in advanced malignant disease. Cancer 1989 (64):1034–1037PubMedCrossRefGoogle Scholar
  6. 6.
    Green MD et al: Phase I trial of escalating doses of doxorubicin administered concurrently with α2-interferon. Cancer Res 1988 (48):2574–2578PubMedGoogle Scholar
  7. 7.
    Muss HB, Welander C, Caponera A et al: Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 1985 (60):721–722Google Scholar
  8. 8.
    Eksborg S, Mattson K: Pharmacokinetics of epirubicin in man. Non-influence of α-interferon. Med Oncol Tumor Pharmacother 1988 (5):131–133PubMedGoogle Scholar
  9. 9.
    Montuoro A, De Rosa L, De Blasio A, et al: Alpha-2a-interferon/melphalan/predisone versus melphalan/predisone in previously untreated patients with multiple myeloma. Br J Haematol 1991 (76):365–368CrossRefGoogle Scholar
  10. 10.
    Ehrsson H, Eksborg S, Wallin I, et al: Oral melphalan pharmacokinetics: influence of interferon-induced fever. Clin Pharmacol Ther 1990 (47):86–90PubMedCrossRefGoogle Scholar
  11. 11.
    Durie BGM, Clouse L, Braich T, et al: Interferon-α2b-cyclophosphamide combination studies: in vitro and phase I-Il clinical results. Sem Oncol 1986 (13):84–88Google Scholar
  12. 12.
    Ozer H, Anderson JR, Peterson BA, et al: Combination trial of subcutaneous interferon-alpha-2b and oral cyclophosphamide in favourable histology non Hodgkin’s lymphoma. Invest New Drugs 1987 (5 suppl):S27–33Google Scholar
  13. 13.
    Chu E, Zinn S, Allegra C: Mechanisms of interaction of gamma-interferon and 5-fluorouracil in a human colon cancer cell line (H630). Proc AACR 1990 (31):420Google Scholar
  14. 14.
    Esgro JJ, Killion JJ, Fidler IJ: Modulation of the antiproliferative effect of floxuridine by interferon-beta against human colon carcinoma cells. Proc AACR 1990 (31):425Google Scholar
  15. 15.
    Elias L, Crissman HA: Interferon effects upon adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 1988 (48):4868–4873PubMedGoogle Scholar
  16. 16.
    Elias L, Sandoval JM: Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Comm 1989 (163):867–874PubMedCrossRefGoogle Scholar
  17. 17.
    Kimoto Y: Combined effect of interferons alpha, beta and gamma on tumor growth in vitro. Gan to Kagaku Ryoho [6T8] 1986 (13):302–307PubMedGoogle Scholar
  18. 18.
    Kimoto Y: Antitumor effects of interferons with chemotherapeutic agents. Gan to Kagaku Ryoho [6T8] 1986(13) :293–301PubMedGoogle Scholar
  19. 19.
    Yamamoto Y, Tanaka H, Namba M: Potentiation of cytotoxic effects of anticancer drugs on human genitourinary neoplastic cells by recombinant gamma interferon. Gan to Kagaku Ryoho [6T8] 1987 (14):699–705PubMedGoogle Scholar
  20. 20.
    Le J, Yip Y, Vilcek J: Cytolytic activity of interferon gamma and its synergism with 5-fluorouracil. Int J Cancer 1984 (34):495–500PubMedCrossRefGoogle Scholar
  21. 21.
    Tan YY, Epstein LB, Armstrong RD: In vitro evaluation of 6 TG and IFNot as a therapeutic combination in HL-60 and natural killer cells. Cancer Res 1989 (49):4431–4434PubMedGoogle Scholar
  22. 22.
    Morikawa K, Fidler IJ: Heterogenous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines. J Biol Resp Mod 1989 (8):206–218Google Scholar
  23. 23.
    Morikawa K, Fan D, Denkins YM et al: Mechanisms of combined effects of γ-interferon and 5-fluorouracil on human colon cancers implanted into nude mice. Cancer Res 1989 (49):799–805PubMedGoogle Scholar
  24. 24.
    Morikawa K, Morikawa R, Killion JJ, et al: Isolation of human carcinoma cells for resistance to a single interferon associated with a cross-resistance to multiple recombinant interferons: α, β and γ. JNCI 1990 (82): 517–522PubMedGoogle Scholar
  25. 25.
    Killion JJ, Fishback R, Littleton T, et al: The antiproliferative activity of fluorodeoxyuridine and interferon alpha against cultured human colon carcinoma cells depends upon the sequence of treatment. Proc AACR 1990 (31):425Google Scholar
  26. 26.
    D’Atri S, Fuggetta MP, Giganti G, et al: Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy. Cancer Immunol Immunother 1988 (27):163–170PubMedGoogle Scholar
  27. 27.
    Wadler S, Goldman M, Lyver A, et al: Phase I trial of 5-fluorouracil and recombinant α2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 1990 (50):2056–2059PubMedGoogle Scholar
  28. 28.
    Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989 (7):1769–1775PubMedGoogle Scholar
  29. 29.
    Ajani JA, Rios AA, Ende K, et al: Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 1989 (8):140–146PubMedGoogle Scholar
  30. 30.
    Clark PI, Slevin ML, Reznek RH et al: Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. Int J Colon Dis 1987 (2):26–29CrossRefGoogle Scholar
  31. 31.
    Rizzo M, Bartoletti R, Selli C, et al: Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma. Eur J Urol 1989 (16):271–277Google Scholar
  32. 32.
    Schornagel JH, Verweij J, ten Bokkel Huinink WW et al: Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. J Urol 1989(142):253–256PubMedGoogle Scholar
  33. 33.
    Bergerat J-P, Herbrecht R, Dufour P, et al: Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer 1988(62):2320–2324PubMedCrossRefGoogle Scholar
  34. 34.
    Trump DL, Ravdin PM, Borden EC, et al: Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. J Biol Response Mod 1990 (9):108–111PubMedGoogle Scholar
  35. 35.
    Kellokumpu-Lehtinen P., Nordman E. (1990). Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase l-Il study. J. Biol. Response Mod. 9:439–444PubMedGoogle Scholar
  36. 36.
    Oliver RTD, Nethersell ABW, Bottomley JM: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal cell carcinoma. Br J Urol 1989 (63):128–131PubMedCrossRefGoogle Scholar
  37. 37.
    Goldstein D, Laszlo J, Rudnick S: Interferon therapy in cancer. In: Oldham RK (ed) Principles of Cancer Biotherapy. Raven Press Ltd, New York, 1987 p 247Google Scholar
  38. 38.
    Comis RL: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 1976 (60):165–176PubMedGoogle Scholar
  39. 39.
    McCleod GRC, Thomson DB, Hersey P: Recombinant interferon alfa-2a in advanced malignant melanoma: A phase l-II study in combination with DTIC. Int J Cancer 1987 (suppl 1):31–35Google Scholar
  40. 40.
    Kirkwood JM, Ernstoff MS, Giuliano A: Interferon alpha-2a and dacarbazine in melanoma. JNCI 1990 (82):1062–1068PubMedGoogle Scholar
  41. 41.
    Grunberg SM, Kempf RA, Itri LM et al: Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985 (69):1031–1032PubMedGoogle Scholar
  42. 42.
    Olesen BK, Ernst P, Nissen MH et al: Recombinant interferon A therapy of small cell and squamous cell carcinoma of the lung. A phase II study. Eur J Cancer Clin Oncol 1987 23:987–989PubMedCrossRefGoogle Scholar
  43. 43.
    Carmichael J, Fergusson RJ, Wolf CR et al: Augmentation of cytotoxicity of chemotherapy by human alpha-interferon in human non-small cell lung cancer xenografts. Cancer Res 1986 (46):4916–4920PubMedGoogle Scholar
  44. 44.
    Berek J, Hacker N, Lichtenstein A et al: Intraperitoneal recombinant α-interferon for salvage immunotherapy in stage III epithelial ovarian cancer. Cancer Res 1985 (45):4447–4453PubMedGoogle Scholar
  45. 45.
    Anger B, Porzsolt F, Leichtle R, et al: A phase l/ll study of recombinant interferon alpha 2a and hydroxyurea for chronic myeloid leukemia. Blut 1989(58):275–278PubMedCrossRefGoogle Scholar
  46. 46.
    Croghan MK, Booth A, Meyskens FL: A phase I trial of recombinant interferon-α and α — difluoromethylornithine in metastatic melanoma. J Biol Response Mod 1988 (7):409–415PubMedGoogle Scholar
  47. 47.
    Calvo F, Jabrane N, Faille A, et al: Quantitative modifications of major histocompatibility complex (MHC) antigens by recombinant gamma interferon in two human breast cancer cell lines. Int J Immunopharmacol 1987 (9):459–468PubMedCrossRefGoogle Scholar
  48. 48.
    van Vliet E, Molenaar JL, Tuk CW et al: Recombinant gamma interferon induces class II major histocompatibility complex antigens on insulinoma cells. Tissue Antigens 1987 (29):195–200PubMedCrossRefGoogle Scholar
  49. 49.
    Alonso MC, Navarrete C, Salana R et al: Modulation of the expression of HLA class II antigens by gamma interferon and phorbol ester TPA on myeloid leukaemia cells. J Immunogenet 1980 (13):255CrossRefGoogle Scholar
  50. 50.
    Gross N, Beck D, Farre S, Carrel S: In vitro antigenic modulation of human neuroblastoma cells induced by IFN-G, retinoic acid and dibutyl cyclic AMP. Int J Cancer 1987 (39):521–529PubMedCrossRefGoogle Scholar
  51. 52.
    Kameyama K, Tone T, Eto H et al: Recombinant gamma interferon induces HLA-DR expression on squamous cell carcinomas, trichilemmoma, adenocarcinoma cell lines and cultured human keratinocytes. Arch Dermatol Res 1987 (269):161–166CrossRefGoogle Scholar
  52. 53.
    Balkwill FR, Stevens MH, Griffin DB et al: Interferon gamma regulates HLA-Dr expression on solid tumours in vivo. Eur J Cancer Clin Oncol 1987 (23):101–116PubMedCrossRefGoogle Scholar
  53. 54.
    Carrington MN, Chedid M, Ting JP-Y, Ward FE: Differential expression of the HLA-DR genes in various melanoma cells treated with interferon gamma; methylation of the HLA-DR alpha gene in these cell lines is not correlated with expression. Hum Immunol 1987 (18):151–161PubMedCrossRefGoogle Scholar
  54. 55.
    Guerry D, Alexander MA, Elder DE, Herlyn MF: Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol 1987 (139):305–312PubMedGoogle Scholar
  55. 56.
    Ruiter DJ, Brocker E-B, Ferrone S: Expression and susceptibility to modulation by interferons of HLA class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance. J Immunogenet 1986 (13):229–234PubMedCrossRefGoogle Scholar
  56. 57.
    Borden EC: Augmented tumor-associated antigen expression by interferons. JNCI 1988 (80):148–149PubMedGoogle Scholar
  57. 58.
    Greiner JW, Guadagni F, Noguchi P et al: Recombinant interferon enhances monoclonal antibody targeting to carcinoma lesions in vivo. Science 1987 (235):895–898PubMedCrossRefGoogle Scholar
  58. 59.
    Rosenblum MG, Lamki LM, Murray JL et al: Interferon induced changes in pharmacokinetics and tumor uptake of 111In-labelled antimelanoma antibody 96.5 in melanoma patients. JNCI 1988 (80):160–165PubMedGoogle Scholar
  59. 60.
    Van den Berg HW, Leahey WJ, Lynch M et al: Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitivities to the antiproliferative effects of tamoxifen. Br J Cancer 1987 (55):255–257PubMedCrossRefGoogle Scholar
  60. 61.
    Iacobelli S, Natoli C, Arno E et al: An antiestrogenic action of interferons in human breast cancer cells. Anticancer Res 1986 (6):1391–1394PubMedGoogle Scholar
  61. 62.
    Dritschilo A, Mossman K, Gray M, Sreeralsan T: Potentiation of radiation injury by interferon. Am J Clin Oncol 1982 (5):79–82PubMedGoogle Scholar
  62. 63.
    Nederman T, Benediktsson G: Effects of interferon on growth rate and radiation sensitivity of cultured human glioma cells. Acta Radiol Oncol 1982 (21):231–234PubMedCrossRefGoogle Scholar
  63. 64.
    Gould MN, Kakria R, Olson S, Borden E: Radiosensitisation of human bronchogenic carcinoma cells by interferon beta. J Interferon Res 1984 (4):123–128PubMedCrossRefGoogle Scholar
  64. 65.
    Namba M, Yamamoto S, Tanaka H et al: Potentiation of cytotoxic effects of anticancer drugs or cobalt-60 gamma rays by interferon on neoplastic cells. Cancer 1984 (54):2262–2267PubMedCrossRefGoogle Scholar
  65. 66.
    Lvovsky E, Mossman K, Levy H, Dritschilo A: Response of mouse tumor to interferon inducer and radiation. Int J Radiat Oncol Biol Phys 1985 (11):1721–1725PubMedCrossRefGoogle Scholar
  66. 67.
    Torrisi J, Berg C, Harler K et al: Phase I combined modality clinical trial of alpha-2-interferon and radiotherapy. Int J Radiat Oncol Biol Phys 1986 (12):1453–1456PubMedCrossRefGoogle Scholar
  67. 68.
    Onishi T, Machida T, Mori Y et al: Hyperthermia with simultaneous administration of interferon using established human renal cell carcinoma heterotransplanted nude mice. Br J Urol 1989 (63):227–232PubMedCrossRefGoogle Scholar
  68. 69.
    Robins HI, Sielaff KM, Storer B et al: Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer. Cancer Res 1989 (49):160901615Google Scholar
  69. 70.
    Rosenberg SA, Lotze MT, Yang JC et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989 (210):474–484PubMedCrossRefGoogle Scholar
  70. 71.
    Rosenberg SA, Lotze MT, Yang JC et al: Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989 (7):1863–1874PubMedGoogle Scholar
  71. 72.
    Atzpodien J, Körfer A, Franks CR et al: Home therapy with recombinant human interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 1990 (335):1509–1512PubMedCrossRefGoogle Scholar
  72. 73.
    Atzpodien J, Körfer A, Evers P et al: Low-dose subcutaneous interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 1990 (2):18–26PubMedGoogle Scholar
  73. 74.
    Krigel RL, Padaric-Shaller KA, Rudolph AR et al: A phase I study of recombinant interleukin-2 plus recombinant β interferon. Cancer Res 1988 (48):3875–3881PubMedGoogle Scholar
  74. 75.
    Krigel RL, Padaric-Shaller KA, Rudolph AR et al: Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol 1990 (8):460–467PubMedGoogle Scholar
  75. 76.
    Redman BG, Flaherty L, Chou T-H et al: A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. J Clin Oncol 1990 (8): 1269–1276PubMedGoogle Scholar
  76. 77.
    Renkonen R, Ristimaki A, Hayry P: Interferon-gamma protects human endothelial cells from lymphokine activated killer cell mediated lysis. Eur J Immunol 1988 (18):1839–1842PubMedCrossRefGoogle Scholar
  77. 78.
    Wagstaff J, Vermorken JB, Schwartzmann G: A progress report of a phase I study of interferon gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2. Cancer Treat Rev 1989 (16 suppl A):105–109Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • John Wagstaff
    • 1
  1. 1.Department of Medical OncologyFree University HospitalAmsterdamThe Netherlands

Personalised recommendations